Stocksigma LogoStocksigma Logo

Mankind Pharma Approves Amalgamation of Wholly Owned Subsidiaries and Reports Q2 Financials

Mankind Pharma approved the Scheme of Arrangement for the amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the

Mankind Pharma Approves Amalgamation of Wholly Owned Subsidiaries and Reports Q2 Financials

Mankind Pharma Ltd · Others (Uncategorized) · 26 Oct 2026, 8:51 pm

Mankind Pharma Approves Amalgamation of Wholly Owned Subsidiaries and Reports Q2 Financials Mankind Pharma approved the Scheme of Arrangement for the amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the company, effective 1st Apr'27, with no new share issuances or cash consideration. The board also noted the merger of Upakarma Ayurveda into Mankind Consumer Products. For Q2 ended 30th Sep'26, consolidated revenue from operations rose 17.33% YoY to ₹4,337.86 crore, while net profit grew 37.67% YoY to ₹716.12 crore. Separately, the board approved raising its investment limit in its Netherlands arm to €50mn to acquire a 70% stake in ACTx.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements